CLINICAL_TRIALS
trial_result
· 2025-02-26
Clinical Trial Update: Avelumab as Neoadjuvant Therapy in Subjects With Urothelial Muscle Invasive Bladder Cancers (AURA Trial) [Phase 2]
Summary
Phase 2 trial evaluating avelumab as neoadjuvant therapy for non-metastatic muscle-invasive bladder cancer has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Jules Bordet Institute | Conditions: Non-metastatic Muscle Invasive Bladder Cancer | Phase 2 | Status: COMPLETED